Fiche publication
Date publication
novembre 2019
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria
Tous les auteurs :
Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, Utikal J, Dabrowski E, Gesierich A, Pföhler C, Terheyden P, Thoms KM, Zimmer L, Eigentler TK, Kirchberger MC, Stege HM, Meier F, Schlaak M, Berking C
Lien Pubmed
Résumé
Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear.
Mots clés
Biomarker, Combined immune checkpoint blockade, Ipilimumab, Nivolumab, Uveal melanoma
Référence
J Immunother Cancer. 2019 11 13;7(1):299
